Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss during tirzepatide treatment is almost always telogen effluvium — a temporary, stress-related shedding triggered by rapid weight loss rather than the medicine itself. It typically begins six to twelve weeks after the weight starts dropping and, for most people, slows and stops without any medication changes. That said, there are real steps you can take to support your hair while your body adjusts. Tirzepatide is a prescription-only weight-management medicine dispensed following clinical assessment; any concerns about side effects are best raised with your prescriber before making changes to your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You weigh noticeably less. Your clothes fit differently. And then, somewhere around the ten-week mark, you notice a cluster of hair on the shower floor. Frustrating, and for many people, alarming enough to Google at 11pm.
The most likely explanation is telogen effluvium. Your hair follicles cycle through growth, transition and a resting phase called telogen. A sudden and significant change to the body (including rapid weight loss) can push a larger-than-usual proportion of follicles into that resting phase simultaneously. Around ten to twelve weeks later, when those hairs shed, you notice the result. The link between tirzepatide and hair loss has been discussed in clinical settings since the SURMOUNT trials, and shedding was reported in a meaningful minority of participants, but it was classified as mild in the overwhelming majority of cases.
Tirzepatide itself does not appear to damage the follicle. What drives the shedding is the physiological stress of losing weight at speed, which is partly why people on lower maintenance doses (where weight loss has slowed) often notice the shedding easing off. The evidence on whether tirzepatide directly causes hair loss points mostly toward the weight-loss mechanism rather than the molecule.
One thing worth noting: thyroid function can shift during significant weight loss, and thyroid changes are themselves a common cause of hair thinning. If you have any reason to suspect a thyroid issue, speak to your GP about a blood test alongside your prescriber review.
The strongest practical lever available to you is what you eat. When appetite falls sharply on tirzepatide, it is easy to lose more protein, iron and zinc than you realise, and hair follicles are among the first structures to feel the pinch when micronutrient supply drops. This is one of the things our prescribers flag at the consultation stage before treatment starts.
Protein is the priority. A reasonable working target during active weight loss is around 1.2 to 1.6 grams per kilogram of body weight daily, though your prescriber or a registered dietitian can give you a figure specific to your circumstances. Eggs, Greek yoghurt, fish, chicken and legumes are all practical options when your appetite is reduced and meals are smaller. Aim for protein at each meal rather than one large hit.
Iron deficiency is the commonest nutritional cause of hair loss in women of reproductive age, and it can develop quietly during a period of reduced food intake. Ferritin (stored iron) is worth checking via a GP blood test if shedding is heavy. Zinc and biotin are frequently cited in the context of hair health; while frank deficiency of either is uncommon in the UK on a varied diet, they can slip during heavy dietary restriction. Biotin supplements are widely available and low-risk, though the NHS tirzepatide patient information rightly places nutritional balance ahead of supplementation as the primary approach.
A practical detail that helps: some people find it easier to hit their protein target by having a high-protein breakfast (Greek yoghurt, eggs, or a protein drink) before the tirzepatide appetite suppression builds across the day. Keep whatever works for you as a consistent morning routine, the same way you store your pen in the fridge door and reach for it on the same day each week.
Most tirzepatide-related shedding is diffuse (spread evenly across the scalp), temporary and self-limiting. But some patterns deserve clinical attention. See your GP or contact your prescriber if you notice any of the following:
Patchy hair loss, particularly round or irregular bald patches, can indicate alopecia areata, an autoimmune condition unrelated to weight loss medicine, which needs its own assessment. Hair loss accompanied by significant fatigue, cold sensitivity, weight gain or irregular periods could point to a thyroid issue. Heavy, accelerating shedding that shows no sign of slowing after six months of stable weight warrants investigation for nutritional deficiency or another underlying cause.
You should also speak to a clinician before adjusting or stopping your tirzepatide because of hair loss alone. Slowing titration pace is sometimes an option worth discussing, and a prescriber can weigh that against your overall progress, with our guidance on how to stop hair loss on Mounjaro a useful resource to read before that conversation. For other side effects affecting daily life (including gastrointestinal symptoms) our guidance on Mounjaro side effects covers the broader picture, and there is specific practical advice on managing diarrhoea from tirzepatide if that is also a concern.
Suspected side effects from any medicine can be reported directly to the MHRA via the Yellow Card scheme. You do not need a clinician to submit a report, patients can do this directly, and the data genuinely informs ongoing safety monitoring.
For the majority of people, telogen effluvium on tirzepatide is self-resolving. As weight loss slows (which it naturally does at higher doses or once maintenance is reached) the physiological stress signal eases. Follicles return to their normal cycle, and regrowth begins. Visible regrowth often starts within three to six months of the shedding peak, though the timeline varies.
Managing expectations matters here. Regrowth hair is often finer at first and may come in at a different texture temporarily. This is normal follicle behaviour during recovery, not a sign that damage is permanent. Gentle scalp care, avoiding aggressive heat styling, and maintaining protein intake all support the process.
If you are considering starting tirzepatide and hair loss is a concern, or if you are already on treatment and want to talk through whether dose timing or nutrition adjustments are right for you, a prescriber review is the right next step. You can find more context on the treatment itself (how it works, what the clinical trials showed, and how the UK programme is structured) on our weight-loss treatment overview, or meet the clinical team who review every consultation at nume. If you are ready to speak to our prescribers about suitability and have your side-effect questions answered as part of the process, the free consultation is the place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.